enGene Therapeutics
ENGNNasdaq CanadaHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Market cap
$113.593 M
$1.70 -1.45%
Close of 6 Nov 2026
As of 6 Nov 2026, enGene Therapeutics (ENGN) has a market capitalization of $113.6M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.
Revenue
—
Not reported
Earnings
-$117.3M
Loss-making
Shares outstanding
67,016,316
Latest filing cover page
P/E ratio
—
Cap ÷ net income
Other share classes
enGene Therapeutics lists more than one class of stock. Company figures above cover all classes combined.
Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap
All 163 →- #104Molecular PartnersMOLN$120.6M
- #105Coherus OncologyCHRS$115.9M
- #106enGene TherapeuticsENGN$113.6M
- #107Cardiol TherapeuticsCRDL$112.1M
- #108Armata PharmaceuticalsARMP$111.2M
What if enGene Therapeutics were worth as much as…
Open the what-if tool →Where these numbers come from
Share counts and financials for enGene Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.